65,437 trials
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Died: PP-ITT — 70.1; 63.8 Percentage of Participants
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Transplant Related Mortality (TRM) — 8.5 percentage of participants
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Melanoma
Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants
Advanced Ovarian Carcinoma · Primary Peritoneal Carcinoma · Ovarian Carcinosarcoma
Primary: Number of Patients Able to Complete 6 Cycles of Treatment. — 17 Participants
Non-Hodgkin Lymphoma
Primary: Number of Patients to Mobilize ≥5 x 10^6 CD34 Cells/kg Autologous PBSC (Efficacy) — 17 Participants
Brain and Central Nervous System Tumors
Primary: Phase 1: Maximum Tolerated Dose (MTD) — 1; 0; 1; 1 participants
Age Related Macular Degeneration
Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…
High Blood Pressure
Primary: Breathing Rate — 9.4; 13.7 Breaths/minute
Labor Analgesia
Primary: Survey to Determine Utility and Effect of Educational Materials — 79; 21; 93; 7 percentage of patients responding — p=<0.0001
Healthy
Primary: Accuracy of SpHb on R1-25 by Arms Calculation — 1.0 g/dL
Breast Cancer · Metastatic Cancer
Primary: Progression-free Survival — 10.3; 15.3 weeks
Parkinson Disease
Primary: Change of Freezing of Gait Questionnaire (FOG-Q) — 12.0; 13.9 score
Edematous Fibrosclerotic Panniculopathy (EFP)
Primary: Investigator Global Assessment of Aesthetic Improvement — 0.7; 0.9; 1.1; 0.5 units on a scale
Obesity, Morbid · Obesity · Weight Loss
Primary: Percent Change From Baseline in Body Mass Index at 28-Weeks — -2.74; -0.85 % change BMI